Magnolol Reduces Atopic Dermatitis-like Symptoms in BALB/c Mice

Ju-Hyun Lee,Dong-Soon Im
DOI: https://doi.org/10.3390/life14030339
2024-03-06
Life
Abstract:In traditional Korean medicines, Magnolia officinalis is commonly included for the remedy of atopic dermatitis, and magnolol is a major constituent of Magnolia officinalis. Its pharmacological effects include anti-inflammatory, hepatoprotective, and antioxidant effects. Using BALB/c mice repeatedly exposed to 1-chloro-2,4-dinitrobenzene (DNCB), magnolol was evaluated in atopic dermatitis-like lesions. Administration of magnolol (10 mg/kg, intraperitoneal injection) markedly relieved the skin lesion severity including cracking, edema, erythema, and excoriation, and significantly inhibited the increase in IgE levels in the peripheral blood. A DNCB-induced increase in mast cell accumulation in atopic dermatitis skin lesions was reversed by magnolol administration, as well as a rise in expression levels of pro-inflammatory Th2/Th17/Th1 cytokines' (IL-4, IL-13, IL-17A, IFN-γ, IL-12A, TARC, IL-8, and IL-6) mRNAs in the lymph nodes and skin (n = 5 per group). In lymph nodes, magnolol reversed DNCB's increase in CD4+RORγt+ Th17 cell fraction and decrease in CD4+FoxP3+ regulatory T cell fraction. The results also showed that magnolol suppressed T cell differentiation into Th17 and Th2 cells, but not Th1 cells. Magnolol suppresses atopic dermatitis-like responses in the lymph nodes and skin, suggesting that it may be feasible to use it as a treatment for atopic dermatitis through its suppression of Th2/Th17 differentiation.
biology
What problem does this paper attempt to address?
The problem this paper attempts to address is the evaluation of the therapeutic effects of magnolol, a major component of Magnolia officinalis, on atopic dermatitis. Specifically, the study assesses whether magnolol can alleviate the symptoms of atopic dermatitis using a mouse model induced by 1-chloro-2,4-dinitrobenzene (DNCB) and explores its mechanism of action. The study found that magnolol significantly alleviated skin lesion symptoms such as desquamation, erythema, and ulcers, and reduced IgE levels in the blood. Additionally, magnolol was able to inhibit the expression of pro-inflammatory cytokines (such as IL-4, IL-13, IL-17A) in lymph nodes and skin, reduce the number of mast cells, and regulate the proportion of T cell subsets. These results suggest that magnolol may be a potential treatment for atopic dermatitis, particularly by inhibiting the differentiation of Th2 and Th17 cells.